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Abstract
Like their normal hematopoietic stem cell counterparts, leukemia stem cells (LSC) in chronic
myelogenous leukemia (CML) and acute myeloid leukemia (AML) are presumed to reside in
specific niches in the bone marrow microenvironment (BMM)1, and may be the cause of relapse
following chemotherapy.2 Targeting the niche is a novel strategy to eliminate persistent and drug-
resistant LSC. CD443,4 and IL-65 have been implicated previously in the LSC niche.
Transforming growth factor (TGF)-β 1 is released during bone remodeling6 and plays a role in
maintenance of CML LSCs7, but a role for TGF-β 1 from the BMM has not been defined. Here, we
show that alteration of the BMM by osteoblastic cell-specific activation of the parathyroid
hormone (PTH) receptor8,9 attenuates BCR-ABL1-induced CML-like myeloproliferative
neoplasia (MPN)10 but enhances MLL-AF9-induced AML11 in mouse transplantation models,
possibly through opposing effects of increased TGF-β 1 on the respective LSC. PTH treatment
caused a 15-fold decrease in LSCs in wildtype mice with CML-like MPN, and reduced
engraftment of immune deficient mice with primary human CML cells. These results demonstrate
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tthat LSC niches in chronic and acute myeloid leukemias are distinct, and suggest that modulation
of the BMM by PTH may be a feasible strategy to reduce LSC, a prerequisite for the cure of CML.
Activation of osteoblastic cells in the bone marrow by PTH alters normal hematopoiesis4.
We therefore tested whether PTH signaling could affect leukemogenesis by using transgenic
mice with osteoblastic cell-specific expression of a constitutively active receptor for PTH
and PTH-related peptide (PPR) under control of the 2.3 fragment of the collagen α 1(I)
promoter (Col1-caPPR mice)8,9 or WT littermates as recipients in the retroviral
transduction/transplantation model of CML-like MPN12. In Col1-caPPR recipients, the
cumulative mortality due to BCR-ABL1-induced CML-like MPN was significantly
decreased (P < 0.001; Fig. 1a) and overall survival significantly prolonged (P = 0.002,
logrank test; Fig. 1b), with half of recipients succumbing to histiocytic sarcoma (HS), a
BCR-ABL1-induced malignancy of monocyte-macrophages (Fig. 1b and Supplementary
Fig. 1a–f) that can arise ~2 months after transplantation under conditions where efficiency of
induction of CML-like MPN is low12,13. An equivalent number of proviral clones,
representing leukemia-initiating cells4, engrafted in WT and Col1-caPPR recipient spleen
(Fig. 1c) and BM (Supplementary Fig. 1g), while homing of BCR-ABL1+ c-Kit+Lin−
Sca-1+ (KLS) cells to BM and spleen (Supplementary Fig. 1h) of Col1-caPPR or WT mice
was not different. Yet, counts of circulating GFP+ leukocytes remained normal in most
Col1-caPPR recipients at a time (20d post-transplant) when leukocytosis was evident in WT
recipients (data not shown, P = 0.03), whereas the absolute number of BM-derived BCR-
ABL1+ (GFP+) KLS cells, defined previously as LSC in this CML model14, was decreased
in Col1-caPPR recipients at the time of morbidity or death (Fig. 1d, P = 0.03, t-test).
Therefore, LSC engrafted but were not maintained in Col1-caPPR recipients.
Rates of LSC apoptosis did not differ (data not shown), but the frequency of cycling GFP+c-
Kit+Lin− (KL) cells in Col1-caPPR recipients was significantly decreased (Fig. 1e and
Supplementary Fig. 1i, P < 0.001, t-test), and the number of viable BM cells in leukemic
Col1-caPPR recipients was significantly reduced (Fig. 1f, P < 0.001, t-test). BCR-ABL1-
dependent myeloid colony formation15 was also significantly reduced from Col1-caPPR-
derived BCR-ABL1+ BM (Fig. 1g, P = 0.02, t-test). The survival of secondary recipients of
BM grafts from leukemic Col1-caPPR donors was significantly prolonged compared to
recipients of WT BM grafts (Fig. 1h, P = 0.04, logrank test). Together, these results
demonstrate that BCR-ABL1-induced CML-like disease is attenuated in Col1-caPPR mice
due to decreased frequency, proliferation and maintenance of the phenotypic LSC and
leukemic progenitor pool in the BMM.
We also transduced WT BM with retrovirus expressing MLL-AF9, the product of human
t(9;11)+ AML that induces aggressive AML in mice11. Interestingly, the survival of Col1-
caPPR recipients was significantly shorter than that of WT recipients (Fig. 1i, P < 0.001,
logrank test). The number of engrafting proviral clones in spleen of Col1-caPPR recipients
was significantly increased compared to WT recipients (5.4 ± 1.3 versus 3.0 ± 1.1,
respectively; P = 0.01, t-test), with similar findings in BM (Fig. 1j). These results
demonstrate that, in contrast to CML-like MPN, MLL-AF9-induced AML is accelerated in
Col1-caPPR recipients, possibly due to an increased number of leukemic clones that engraft
and persist in the Col1-caPPR BMM.
As the BMM of Col1-caPPR mice is characterized by increased osteoclasts and bone
remodeling8, we treated WT and Col1-caPPR recipients of BCR-ABL1-transduced WT BM
with an Fc-fusion protein (OPG-Fc) of osteoprotegerin, a decoy receptor for RANKL that
can reverse the bone phenotype in Col1-caPPR mice16. OPG-Fc treatment significantly
increased the frequency of CML-like MPN in Col1-caPPR recipients from 40% to 90% (Fig.
2a and Supplementary Table 1; P = 0.02, Chi square test), although the increase in mortality
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tin Col1-caPPR recipients treated with OPG-Fc did not reach statistical significance (P =
0.06, log-rank test; Supplementary Fig. 2a). Interestingly, treatment with the osteoclast
inhibitor zolendronate did not restore CML-like MPN (data not shown), possibly due to the
distinct mechanisms of OPG-Fc (RANKL antagonism) and zolendronate (inhibition of
isoprenoid biosynthesis) on bone remodeling.
Anabolic effects of PTH on bone formation during bone remodeling are diminished in
Tgfb1−/− mice17. Consistently, TGF-β 1 protein (Fig. 2b) and biologically active TGF-β 1
(Fig. 2c, P = 0.02, t-test) were increased in the bones of Col1-caPPR mice. Whereas TGF-
β 1+ osteoblasts and osteoclasts are increased in Col1-caPPR recipients, OPG-Fc treatment
eliminated these cells (Fig. 2d and Supplementary Fig. 2b) and significantly reduced nuclear
pSMAD2/3, downstream of TGF-β  receptor I (TGFβ RI), in hematopoietic cells from WT
and Col1-caPPR mice with CML (P = 0.004 and P = 0.02, respectively, t-test; Fig. 2e and
Supplementary Fig. 2c). Whereas there was no direct effect of OPG-Fc on BCR-ABL1+
cells in vitro (Supplementary Figs. 2d,e), we hypothesized that increased TGF-β 1 signaling
in the Col1-caPPR BMM might suppress CML progenitor growth, given that these cells
have increased expression of TGFβ RI compared to AML cells (P = 0.027, t-test,
Supplementary Fig. 3a–c)18,19. Indeed, TGF-β 1 significantly inhibited the in vitro growth of
BCR-ABL1+ K562 but not MLL-AF9+ THP-1 cells (Fig. 2f), and direct intrafemoral
injection of TGF-β 1 in WT recipients with CML-like MPN dramatically reduced BM
cellularity (Fig. 2g).
We further hypothesized that the LSC niche might differ between spleen and BM of Col1-
caPPR recipients. In contrast to elevated TGF-β 1 in Col1-caPPR bone, TGF-β 1 levels in
Col1-caPPR spleen were similar to those in WT spleen and bone (Fig. 2h). CML-like MPN
could be induced in secondary recipients by transplantation of BM from WT or splenocytes
from WT or Col1-caPPR primary leukemic mice, but not by Col1-caPPR BM (Fig. 2i).
However, splenectomy of WT or Col1-caPPR primary recipients prior to transplanation of
BCR-ABL1-transduced BM did not affect leukemic mortality (Supplementary Fig. 3d),
suggesting differential maintenance of LSC in the BM versus spleen of Col1-caPPR mice,
possibly due to different TGF-β 1 levels in the respective niches. Taken together, these data
support a model in which TGF-β 1 generated by increased bone remodeling in Col1-caPPR
mice suppresses BCR-ABL1-mediated MPN and may impair the maintenance of LSC.
To validate this, we assessed whether TGF-β 1 blockade could increase the incidence of
CML in Col1-caPPR recipients. Lentiviral shRNA knockdown of TGFβ RI (to ~60% of
control, Supplementary Fig. 4a) in BCR-ABL1-expressing cells accelerated the development
(Fig. 3a; P = 0.007, logrank test) and increased the overall incidence (P = 0.04, Fisher’s
exact test; data not shown) of fatal CML-like MPN in Col1-caPPR recipients relative to
control scrambled shRNA lentivirus. Conversely, overexpression of TGFβ RI in MLL-AF9+
AML (Supplementary Fig. 4b) resulted in modest but significant prolongation of survival of
Col1-caPPR recipients (Fig. 3b, P = 0.02, logrank and Wilcoxon tests). In response to TGF-
β 1, nuclear pSMAD2/3 was signficantly increased in CML LSCs compared to saline-treated
cells (P = 0.01, t-test), whereas pSMAD2/3 staining was similar in AML LSCs with and
without TGF-β 1 treatment (Fig. 3c,d). As described previously for CML LSCs7, staining for
FoxO3a was predominantly nuclear with low pAKT staining (Supplementary Fig. 5a), while
the percentage of CML LSC with nuclear pSMAD2/3 was significantly higher in Col1-
caPPR than in WT mice (P = 0.02, t-test, Supplementary Fig. 5b). These data suggest that
TGF-β 1 derived from the BMM in Col1-caPPR recipients suppresses CML-like MPN, while
MLL-AF9-induced AML is insensitive to this effect due in part to lack of TGFβ RI
expression and/or higher constitutive pSMAD2/3 signaling.
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tTreatment of WT Balb/c mice by continuous infusion of PTH prior to transplantation of
BCR-ABL1-transduced BM caused a transient increase in blood calcium levels20
(Supplementary Fig. 6a) and a reduction in splenomegaly (Supplementary Fig. 6b), but did
not alter LSC engraftment (Supplementary Fig. 6c) or prolong overall survival (data not
shown). However, PTH treatment significantly reduced the efficiency of transplantation of
CML-like MPN to secondary recipients (Supplementary Fig. 6d,e), with limiting dilution
analysis demonstrating a 15-fold reduction in BM LSC frequency (1 in 6.4×106 BM cells in
PTH-treated versus 1 in 4.3×105 BM cells in saline-treated donors, P = 0.0006; Fig. 4a).
This correlated with increased overall survival of all secondary recipients of BM from PTH-
treated donors (P=0.03, Wilcoxon test; Fig. 4b), an effect observed in all cohorts except
recipients of the lowest cell dose (Supplementary Fig. 6f). Treatment of WT mice with
established CML-like MPN (Supplementary Fig. 7a,b) with imatinib alone or in
combination with intermittent infusions of PTH resulted in similar prolongation in survival
(Fig. 4c, P<0.0001 vs saline-treated controls), with long-term disease-free survival observed
predominantly in the cohort treated with PTH + imatinib (33% vs 6% with imatinib alone).
PTH treatment, alone or with imatinib, significantly decreased the percentage of cycling KL
cells compared to imatinib monotherapy (Fig. 4d; P = 0.02 and P = 0.04, respectively, t-
test).
To extend these results to human CML, we injected total BM cells (97–100% Ph+ by FISH,
data not shown) from seven untreated subjects with CML in chronic phase into NOD-SCID
interleukin-2 receptor γ c−/− (NSG) recipient mice pretreated with saline or PTH.
Engraftment of human CD45 leukocytes, assessed in BM aspirates by flow cytometry or
estimated by levels of human β -glucuronidase transcripts as determined by qRT-PCR
(Supplementary Fig. 7c), did not differ significantly between saline- and PTH-treated mice
(0.2% to 4.8%, Fig. 4e, left panel). When results from recipients of different subject samples
were pooled21 to minimize the known variability of engraftment of human CML cells in
immunodeficient mice22, PTH treatment was associated with a significant decrease in
leukemic engraftment (Fig. 4e, right panel, P=0.049, t-test). These data suggest that
modulation of the niche is also deleterious to human CML progenitors, and while
conclusions from xenograft studies must be drawn with caution, the results provide some
support for testing PTH in human subjects with CML.
In this report, we show that modulation of the BMM can alter the course of leukemia in a
physiologically accurate and quantitative mouse model of human CML. We also provide
evidence that the LSC niche in MLL-AF9+ AML is distinct from that in CML. Our data
suggest that the beneficial effect of PTH in CML is mediated via suppressive effects of
TGF-β 1, secreted by a BMM characterized by increased bone turnover, on CML LSC,
although we cannot exclude a role for other cytokines induced by PTH signaling. In
contrast, the acceleration of MLL-AF9+ AML in Col1-caPPR mice may reflect decreased
sensitivity to TGF-β 1 or increased size of the niche for AML LSC. Our findings differ from
those of Naka et al.7, and this may reflect the known influence of dose and context on the
effects of TGF-β 1, with supraphysiologic levels of TGF-β 1 mediating negative effects on
CML LSC in our model. In conclusion, our results suggest that targeting the hematopoietic
microenvironment through PTH may render it hostile for CML cells, raising the possibility
of altering the tumor microenvironment as a novel and potentially complementary approach
to tumor cell-specific therapeutics.
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tOnline Methods
Mice
We purchased Balb/c and NOD SCID interleukin (IL)-2 receptor γ  deficient (NSG) mice
from Charles River Laboratories (Wilmington, MA) and Jackson Laboratory (Bar Harbor,
ME), respectively.
BM transduction and transplantation
Alternatively to MSCV-IRES GFP BCR-ABL1, we also generated MSCV-IRES RFP BCR-
ABL1 or MSCV-IRES RFP TGFβ RI (cloned into the MSCV-IRES RFP vector as an EcoRI
fragment) red fluorescent BCR-ABL1- or TGFβ RI expressing retrovirus. For the generation
of lentivirus expressing the TGFβ RI-knockdown or scrambled short hairpin (sh) RNA, we
transfected 293 cells with GIPZ scrambled or GIPZ RMM4431-99440663 shRNA (Open
Biosystems, Huntsville, AL) and the genes encoding the envelope proteins Δ 8.9 and VSV-G.
We tested viral supernatants for efficient knockdown of TGFβ RI by qPCR after infection of
3T3 fibroblasts, and assessed knockdown of TGFβ R1 in leukemic cells by RT-qPCR of
sorted GFP+ (GIPZ+ lentiviral vector) and RFP+ (BCR-ABL1+) cells. TGFβ RI-specific
primers were 5′ -CAGCTCCTCATCGTGTTGGTG-3′  (forward) and 5′ -
GCCCCTGTTTTTGAAGATGGTG-3′  (reverse).
In homing assays, we transplanted 2.6 × 106 5-FU-treated, BCR-ABL1-transduced BM cells
intravenously into 11 WT and 11 Col1-caPPR mice. 18 hours later, we analyzed BM and
spleen cells of recipient mice from either genotype by flow cytometry for KLS cells and
Annexin-positivity (Invitrogen, Grand Islan, NY) according to the manufacturer’s
instructions.
For xenotransplantation, we intravenously injected 11–50 × 106 frozen total BM cells from 7
different untreated subjects with CML in chronic phase into one to two irradiated (300 cGy)
saline- and one to two irradiated PTH-treated NSG mice per CML subject. Prior
fluorescence in-situ hybridization revealed positivity for the BCR-ABL1 translocation in
>95% of cells. Saline- and PTH-treatment by osmotic minipump, as described below, was
initiated 4 weeks prior to xenotransplantation and was continued for 14 weeks thereafter.
In the secondary transplant experiments in the FVB/Col1-caPPR background, we injected
2.5 × 106 BM or spleen cells from WT FVB or Col1-caPPR mice on day 19 after primary
transplantation with BCR-ABL1+ cells into WT recipients. Flow cytometric analysis of PB
before harvesting of BM and spleen cells of donor animals revealed fully established CML-
like MPN in all donors with a range of 9.9–20.9% CD11b+ GFP+ cells in the WT donor
mice and a range of 19.6–37.7% CD11b+ GFP+ cells in the Col1-caPPR donor mice. We
transplanted BM or spleen grafts from 16 or 10 different, individual donors per FVB WT or
Col1-caPPR donor group, respectively, into four recipients each, two of which received a
BM and two a spleen graft.
For the secondary transplantation in the Balb/c background (limiting dilution experiment),
we treated primary WT Balb/c mice with saline versus human PTH (1–34) via osmotic
minipump for 4 weeks prior to transplantation with BCR-ABL1+ cells. Upon full
establishment of CML on day 17, we harvested BM from 5 saline- versus 5 PTH-treated
primary animals and pooled the BM within one treatment group. We then transplanted BM
from a saline- versus a PTH-treated BM environment in limiting dilution of 2 × 106, 106, 7 ×
105, 2 × 105, 7 × 104 and 2 × 104 cells into 5 recipients each.
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We digested genomic DNA from BM or spleen of leukemic WT or Col1-caPPR mice with
Bgl II, transferred to Nylon membranes and hybridized with a radioactively labeled probe
from the GFP gene, in order to detect distinct proviral integration sites. Single copy DNA
represents control DNA from a cell line that contains a single BCR-ABL1 provirus.
TGF-β1 luciferase assay
We transiently transfected Hep3B cells with a TGF-β 1-responsive luciferase promoter
(CAGA-luc) and a transfection control Renilla luciferase (pRL-TK) vector with
Lipofectamine 2000. Forty-eight hours after transfection, cells were serum starved in 1%
FBS Optimem I and then incubated for 16 hours with the supernatants from crushed bones
from WT or Col-1caPPR mice. As negative and positive controls, cells were incubated with
either PBS or 5 ng/ml TGF-β 1 (R&D systems). Experiments were performed in triplicate.
Subsequently, we lysed the cells and measured luciferase reporter activity by Dual Reporter
Assay (Promega), as described23. We determined relative luciferase activity as the ratio of
Luciferase units to Renilla.
Splenectomy
7 days before transplantation, we anesthesized mice and made an incision below the left
ribcage. We then incised the peritoneum aseptically and grasped the spleen. We tied off
splenic vessels securely and removed the spleen, subsequently suturing the the peritoneum
and skin.
Analysis of diseased mice
We diagnosed the different BCR-ABL1-associated diseases in this mouse model, namely
CML-like MPN, B-cell acute lymphoblastic leukemia (B-ALL) or HS and MLL-AF9-
induced AML, based on clinicopathological criteria, as described4,11,12. We assessed the
leukemic burden in diseased animals weekly by a Vetscan 5 HM (Abaxis, Union City,
California) complete blood count analyzer and by staining leukocytes from PB with a
phycoerythrin (PE)-conjugated antibody to CD11b (myeloid cells) (Biolegend, San Diego,
CA) in CML-like MPN, a PE-conjugated antibody to BP-1 (BD Biosciences, San Jose, CA)
in the case of B-ALL or an allophycocyanin-conjugated antibody to CD11b (BD
Biosciences, San Jose, CA) and a PE-conjugated antibody to Gr-1 (eBioscience, San Diego,
CA) in the case of AML and analysing for expression of GFP. We also stained leukocytes
with an antibody to TGFβ RI (Millipore, Billerica, MA, USA) and a secondary PE-
conjugated anti-rabbit-IgG antibody.
By flow cytometry we analysed BM aspirates, which we obtained as described4, for
expression of GFP, Mac-1, Gr-1, lineage (B220, CD5, Gr-1 and Ter119), c-Kit and Sca-1
and for cycling status by Hoechst 33342 (37 C for 30 minutes) staining on a BD LSRII
(Becton Dickinson). We measured cell viability by trypan blue-staining and counting of live
cells on a Cellometer Vision (Nexcelom Bioscience LLC, Lawrence, MA).
We assessed engraftment of human cells in NSG mice by flow cytometry using anti-human
CD45 (BD Biosciences, Franklin Lakes, NJ). Human hematopoietic engraftment was also
measured by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) for
human beta-glucuronidase (GUS) transcripts (forward primer: 5′ -
GTCTGCGGCATTTTGTCGG-3′ , reverse primer: 5′ -ACCTCCCGTTCGTACCACA-3′ ); a
standard curve relating human CD45 expression to human GUS transcripts was used to
estimate % human engraftment for those samples where hCD45 was not measured directly.
To quantify leukemic engraftment, we performed qRT-PCR for BCR-ABL1 using 5′ -
GTGCAGAGTGGAGGGAGAAC-3′  (forward) and 5′ -ATGCTACTGGCCGCTGAA-3′
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t(reverse) primers, and used these data to estimate the percentage of BCR-ABL1+ cells based
on a standard curve (Supplementary Fig. 7).
For assessment of the incidence of CML in different transplants, we used the following
criteria to define CML: Primary transplants: WBC >15,000/ul and >4% GFP+ Mac-1+ cells
in PB or death due to CML (hepatosplenomegaly and pulmonary congestion and
hemorrhages), secondary transplants: WBC >10,000/ul or >1% GFP+ Mac-1+ cells in PB.
We defined AML by the presence of Gr-1+ GFP+ myeloid blasts in the PB and massive
infiltration of the liver and spleen by these cells.
Histopathology of diseased mice
We took tissue samples of lung, liver, spleen and bone from every deceased mouse and
processed, embedded, sectioned and stained them with hematoxylin & eosin for
histopathological analysis or subjected to immunohistochemistry analysis for TGF-β 1
(Abcam, Cambridge, MA) following standard procedures. We decalcified bones in 0.5 M
EDTA. We performed tartrate-resistant acid phosphatase (TRAP) staining on bones from the
osteoprotegerin-experiment using 50mM tartrate in acetate buffer and TRAP reagent in
N,N-dimethylformamide, with counterstaining performed with methyl green.
A blinded pathologist counted the percentage of hematopoietic cells positive for
pSMAD2/3.
Drug treatment
We injected 3 mg/kg of rat or human osteoprotegerin-Fc (OPG-Fc) chimera (from Dr.
Ernestina Schipani) subcutaneously every other day (three times a week) as described16
beginning 1 week prior to tranplantation. We implanted osmotic minipumps (Alzet,
Cupertino, CA) as described by the manufacturer. We filled the pumps the previous day
with either saline or PTH (resuspended as described20) to allow a daily dose of 80 μ g/kg for
a total of 14 days and left them in sterile saline at 37 C overnight, and changed pumps every
two weeks. We initiated treatment 4 weeks before transplantation and continued until the
animal’s death.
For the daily subcutaneous injections (intermittent dosing regimen), we administered human
PTH (1–34) or saline at 80 μ g/kg/d. We crushed a 100 mg tablet of imatinib, resuspended it
in saline, spun, filtered and subcutaneously injected this daily, beginning on day 10 after
transplantation.
We performed intrafemoral injections with PBS (left femur) or 250 ng TGF-β 1 (right femur)
(Sigma-Aldrich, St. Louis, MO) daily on days 15–18 after transplantation of BCR-ABL1-
transduced BM into WT FVB recipients.
Western Blotting
We crushed and filtered bones or the spleen of a mouse, and prepared lysates in RIPA buffer
(50mM Tris Hcl pH7.4, 150mM NaCl, 1% Triton X-100, 1% NaDOC, 0.1% SDS, 1mM
EDTA), 50mM NaF, 1mM Na3VO4, aprotinin and PMSF. Before loading, we measured the
total protein content of lysates by the Bradford dye-binding method (Bio-Rad, Hercules,
CA), equalized samples for protein content and boiled them in sample buffer containing
DTT. We blotted the proteins onto a PVDF membrane and probed with an antibody to TGF-
β 1 (Abcam, Cambridge, MA). We then reprobed the membrane with an antibody to actin
(Santa Cruz, Santa Cruz, CA). We quantified Western blots by ImageJ software by forming
the ratio between expression levels of TGF-β 1 and the sample’s respective actin control.
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We plated K562 or MLL-AF9+ THP-1 cells in sixplicate at 100,000 cells per well of a 6-
well plate in RPMI with 5ng/ml TGF-β 1 or vehicle. In a separate experiment, we incubated
105 K562 cells with 130 ng/ml OPG-Fc or saline, as described24, and assessed daily for cell
number and viability.
For the methylcellulose colony assays, we plated 2×104 total BM or 2×105 spleen cells from
WT or Col1-caPPR recipients of BCR-ABL1+-transduced BM on day 21 after
transplantation in triplicate in cytokine-free methylcellulose (M3231, Stem Cell
Technologies, Vancouver, Canada) supplemented with 100 pg/ml IL-3 (Peprotech, Rocky
Hill, NJ). We scored colonies after 10 days. We used serial replating assays in
methylcellulose (M3434) for generation of MLL-AF9+ immortalized colony-forming cells
for immunofluorescence studies, as described25.
Immunofluorescence
We prepared cytospin preparations of BCR-ABL1+ or MLL-AF9+ KLS or lineage negative
cells, respectively, on poly-L-lysine covered glass coverslips and stained them for
immunofluorescence analysis with anti-pSMAD 2/3, pAkt (Cell Signaling, Danvers, MA)
and Foxo3a (Sigma, St. Louis, MO), with secondary antibody staining by anti-rabbit Alexa
Fluor 647 (Invitrogen, Grand Island, NY), as described7. We visualized the cells by a Nikon
Eclipse Ti confocal laser microscope and individually quantitated by ImageJ software.
Serum calcium measurement
We added plasma to the calcium-detection agent and measured total calcium concentration
of PB according to the manufacturer’s instructions (Stanbio Laboratory, Boerne, TX).
Additional statistical Methods
We determined the statistical significance of the incidence of CML or survival rates in
different treatment groups by Fisher’s Exact or Chi-square test. We used L-Calc software
(Stemcell Technologies, Vancouver, Canada) to calculate LSC frequency by Poisson
statistics.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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BCR-ABL1-induced CML-like MPN is attenuated in Col1-caPPR recipients. (a and b)
Cumulative mortality from CML-like MPN (a) and overall survival (b) for WT (n=20, solid)
or Col1-caPPR (n=26, dashed) recipients of BCR-ABL1-transduced WT BM (P< 0.001 and
P = 0.002, respectively; logrank tests). (c) Disease clonality in spleens of WT (lanes 1–9)
and Col1-caPPR (lanes 10–22) recipients (WT, 6.6±2.1 clones; Col1-caPPR, 7.2±2.1 clones;
P = 0.52, t-test). (d) Absolute number of GFP+ (BCR-ABL1+) KLS cells in the BM of Col1-
caPPR mice (P = 0.03, t-test, gray bar, n=20) versus WT mice (black bar, n=20). (e)
Hoechst+ BCR-ABL1+ cycling c-Kit+Lin− cells in the BM of Col1-caPPR (gray) mice
compared to WT mice (black) (P < 0.001, t-test). (f) Absolute number of viable BM cells
from Col1-caPPR (gray) versus WT (black) recipients of BCR-ABL1-transduced BM (P <
0.001, t-test). (g) Number of colonies in methylcellulose from BM cells (squares) from
Col1-caPPR (open squares) or WT (solid squares) mice with CML-like MPN (P = 0.02, t-
test) and from spleen cells (circles) from Col1-caPPR (open circles) or WT (solid circles)
mice with CML-like MPN (P = 0.02, t-test). (h) Overall survival for WT secondary
recipients of BCR-ABL1+ BM grafts from a WT (solid, n=30), compared to a Col1-caPPR
(dashed, n=18) microenvironment (P = 0.04). (i) Survival curves for WT (n=18, solid) or
Col1-caPPR (n=21, dashed) recipients of MLL-AF9-transduced WT donor BM (P < 0.0001,
logrank test). (j) Clonality of MLL-AF9+ AML-like disease in spleen of WT recipients
(lanes 2–7) compared to spleen of Col1-caPPR recipients (lanes 8–14) (P = 0.01, t-test) and
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tin BM of WT (lane 15) or Col1-caPPR recipients of MLL-AF9-transduced WT BM (lanes
16–17).
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tFigure 2.
TGF-β 1 signaling is increased in the bones of Col1-caPPR mice and suppresses the growth
of BCR-ABL1+ cells in vitro. (a) Incidence of CML-like MPN in WT (left) and Col1-caPPR
(right) mice treated with osteoprotegerin (WT: light gray, Col1-caPPR: white, n=10) or
saline (wt: black, Col1-caPPR: dark gray, n=10) (P = 0.02, Chi-square). (b) Immunoblotting
of lysates from crushed bone from WT or Col1-caPPR mice probed with antibodies to TGF-
β 1 (molecular mass 25 kDa) or actin (42 kDa) (mean intensity of TGF-β 1 bands normalized
to actin control: WT, 0.6±0.2; Col1-caPPR, 2.5±0.3; P < 0.001, t-test) (c) Bioactive TGF-β 1
in Col1-caPPR bones (white bar, n=8) compared to WT bones (dark gray bar, n=9) (P =
0.02, t-test). (d) Immunohistochemistry (top) for TGF-β 1 and hematoxylin & eosin stains
(bottom) (Scale bar indicates 100 μ m) on bones of Col1-caPPR mice with CML-like MPN
treated with saline (left) or OPG-Fc (right). The arrows depict TGF-β 1+ osteoblastic cells
(bold arrow) and osteoclasts (thin arrow). (e) Immunohistochemistry (Scale bar indicates
100 μ m) for pSMAD2/3 (detected by immunoperoxidase using yellow/brown horseradish-
peroxidase chromogen) on bones of representative Col1-caPPR mice (bottom) with CML-
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tlike MPN treated with saline (left) or OPG-Fc (right). (f) Growth of BCR-ABL1+ K562
(circles) and MLL-AF9+ THP-1 (triangles) cells in the presence of vehicle (solid line) or
TGF-β 1 (dashed line); the differences in cell number at day 3 and 4 were significant (P <
0.001, t-tests). (g) Hematoxylin-eosin-stained sections of BM of a representative (n=3) WT
mouse with CML-like MPN treated by intrafemoral injections with PBS (left panel) or TGF-
β 1 (right panel) (Scale bar indicates 100 μ m). (h) Immunoblotting of lysates from crushed
bone or spleen from WT or Col1-caPPR mice with CML-like MPN probed with an antibody
to TGF-β 1 as in b. (i) Overall survival of WT secondary recipients of BCR-ABL1+ BM or
spleen grafts from a WT (BM: solid, n=30; spleen: long dashes, n=24), compared to a Col1-
caPPR (BM: dots, n=18; spleen: short dashes, n=20) microenvironment. Significant
differences in survival (logrank tests) are indicated.
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Modulation of TGFβ RI on leukemic cells differentially affects BCR-ABL1+ (chronic) and
MLL-AF9+ (acute) myeloid neoplasms in a Col1-caPPR microenvironment. (a) Survival
curves for WT or Col1-caPPR recipients of BCR-ABL1-transduced WT BM that was co-
transduced with lentivirus expressing either scrambled shRNA (WT: solid line; Col1-caPPR:
dotted line) or Tgfbr1 shRNA (WT: long dashes; Col1-caPPR: short dashes). Survival of
Col1-caPPR recipients of BCR-ABL1+ Tgfbr1 shRNA+ BM was significantly shortened (P
= 0.007, logrank test) compared to Col1-caPPR recipients of BCR-ABL1+ scrambled
shRNA+ BM. All Col1-caPPR recipients of BCR-ABL1+ Tgfbr1 shRNA+ BM succumbed
to CML-like MPN. (b) Survival curves for WT or Col1-caPPR recipients of WT BM
transduced with MLL-AF9 retrovirus alone (WT: solid line; Col1-caPPR: dotted line) or co-
transduced with a retrovirus expressing TGFβ RI (WT: long dashes; Col1-caPPR: short
dashes). Survival of Col1-caPPR recipients of MLL-AF9+ TGFβ RI+ BM (n=10) was
significantly prolonged (P = 0.02, logrank test) compared to Col1-caPPR recipients of BM
transduced with MLL-AF9 only (n=8). (c) pSMAD2/3 immunofluorescence staining of Lin−
MLL-AF9+ (left) or BCR-ABL1+ KLS cells treated in vitro with 5 ng/ml TGF-β 1 (bottom)
or saline (top). (d) Quantitation of individual cells from c by confocal microscopy.
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tpSMAD2/3 staining was significantly increased in CML-initiating cells treated with TGF-β 1
compared to saline-treated cells (P = 0.01, t-test), but not in AML-initiating cells.
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PTH treatment reduces leukemia burden and LSC abundance in wt mice and leads to more
longterm survivors in combination with imatinib. (a) Frequency of leukemia-free untreated
secondary recipients of BCR-ABL1+ BM from saline- (black circles) or PTH- (open
squares) treated donors in relation to the dose of transplanted bone marrow. The lines fitted
by regression analysis (L-Calc) allow estimation of leukemia-initiating cell frequency,
which was significantly lower in recipients of BM from PTH-treated donors (P = 0.0006).
(b) Overall survival of WT secondary recipients of BCR-ABL1+ BM grafts from WT mice
treated with PTH (dotted line, n=27) compared to WT mice treated with saline (solid line,
n=29) (P = 0.03, logrank test). (c) Overall survival of WT recipients of BCR-ABL1-
transduced BM treated with daily subcutaneous injections of saline (solid line, n=19) or
PTH (dotted line, n=19), imatinib (long dashes, n=18) or a combination of PTH and imatinib
(short dashes, n=18), randomized prior to transplantation. (d) Percentage of cycling GFP+c-
Kit+Lin− cells is significantly decreased in animals treated with PTH with or without
imatinib (P = 0.04, t-test) compared to imatinib alone. (e) Levels (mean and s.d.) of human
hematopoietic engraftment (measured or estimated percentage of hCD45+ leukocytes, left
panel) or BCR-ABL1+ engraftment (estimated by levels of BCR-ABL1 transcripts, right
panel) in BM aspirates from individual NSG recipients of primary human CML subject
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tsamples (n=7) that were treated with either saline or PTH (P = 0.049, t-test). Recipients of
BM grafts from the same CML subject sample are indicated by the individual symbols. The
two samples in the PTH-treated cohort at the bottom of the plot had BCR-ABL1 transcript
levels that were below the level of detection (estimated <0.001%) despite detectable levels
of human cell engraftment.
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